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Abstract
Fish oil (FO) has been shown to have anti-inflammatory properties in animal models of inflammatory bowel disease, but how fish peptides (FP) influence
intestinal inflammation has been less studied. Male Wistar rats, divided into five groups, were included in a 4-week dietary intervention study. Of the
groups, four were exposed in the fourth week to 5 % dextran sulfate sodium (DSS) to induce colitis, while one group was unexposed. The diets were:
(1) control, (2) control + DSS, (3) FO (5 %) +DSS, (4) FP (3·5 %) +DSS, (5) FO+ FP +DSS. Following DSS intake, weight and disease activity
index (DAI) were assessed, and histological combined score (HCS), selected colonic PG, cytokines, oxidative damage markers and mRNA levels were
measured. FP reduced HCS, tended to lower DAI (P= 0·07) and reduced keratinocyte chemoattractant/growth-regulated oncogene levels, as compared
with the FO diet. FP also reduced mRNA levels of Il-6 and Cxcl1, although not significantly. FO intake increased the DAI as compared with DSS alone.
PGE3 levels increased after the FO diet, and even more following FO + FP intake. The FP diet seems to have a protective effect in DSS-induced colitis as
compared with FO. A number of beneficial, but non-significant, changes also occurred after FP v. DSS. A combined FO+ FP diet may influence PG
synthesis, as PGE3 levels were higher after the combined diet than after FO alone.
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Ulcerative colitis (UC) is an inflammatory bowel disease (IBD)
with a chronic relapsing course, affecting the colon mucosa to a
variable extent and resulting in bloody diarrhoea(1). Dextran
sulfate sodium (DSS)-induced colitis has been used as an experi-
mental model for UC, being clinically and histomorphologically
reminiscent of the human disease. Dietary n-3 PUFA in exper-
imental rodent models of IBD, including DSS colitis, have
shown beneficial effects(2,3). However, data concerning the
anti-inflammatory effect of marine PUFA supplements in
patients with UC are inconsistent(4–6). It is therefore of interest
Abbreviations: DAI, disease activity index; DSS, dextran sulfate sodium; FO, fish oil; FP, fish peptide; GRO, growth-regulated oncogene; HCS, histological combined score;
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to investigate whether dietary supplements other than fish oil
(FO) can have beneficial effects on intestinal inflammation.
FO may have anti-inflammatory effects through several
mechanisms, including an alteration of the substrate from
20 : 4n-6 (arachidonic acid) to 20 : 5n-3 (EPA) and 22 : 6n-3
(DHA) in cell membrane phospholipids. This results in eicosa-
noids that have lower inflammatory potential, such as PGE3
and leukotriene B5
(7). Intake of FO reduced mononuclear cell
production of pro-inflammatory cytokines such as IL-1β and
TNFα after endotoxin stimulation(8).
Fish peptides (FP) seem to have tissue reparative properties
based on several small studies in animals and human subjects.
A commercially available fish hydrolysate, containing 75–80
% protein constituents, reduced non-steroidal anti-inflamma-
tory drug (NSAID)-induced mucosal injury in small intestine
in mice(9). NSAID-induced damage in small intestine and
dyspeptic symptoms decreased in human volunteers(10).
Furthermore, a dietary supplement containing bioactive pep-
tides and amino acids seemed to beneficially affect symptoms
and intestinal permeability in IBD patients(11).
In a previous study, we found that regular intake of Atlantic
salmon for 8 weeks in mildly active UC patients reduced the
symptoms of disease activity and improved the fatty acid pro-
file in plasma as well as in colon samples(12). Fish fillets may
contain bioactive proteins and peptides in addition to marine
fatty acids. Oxidative stress, caused by an imbalance between
the formation of reactive oxygen species and counteracting
antioxidants occurs in several chronic inflammatory con-
ditions, including IBD(13). Increasing the antioxidant levels
might reduce tissue damage and the inflammatory process.
Fish and fish protein may have such an antioxidant potential.
A peptide fraction from fish hydrolysate seemed to have an
antioxidant effect compared with the natural antioxidant
α-tocopherol(14). In obese subjects consuming cod, the con-
centration of malondialdehyde, a measure of lipid oxidation,
was reduced in blood(15).
The aim of this study was to evaluate possible anti-
inflammatory effects of dietary hydrolysed salmon peptides,
also named fish peptides (FP), in DSS-induced colitis in rats.
Furthermore, our aim was to compare dietary intervention
with FP to that of FO or combined FO + FP and assess the
impact on disease activity, selected markers of inflammation
and protein oxidative damage in colon tissue samples.
Experimental methods
Animals and husbandry
A total of fifty male Wistar rats (Taconic), 12 weeks old, with a
weight of approximately 360 g at arrival, were placed in
Makrolon III cages in an open system, with five animals in
each cage. They were kept under standard laboratory condi-
tions with 12 h dark–12 h light cycles and temperature 22 ±
1°C, relative humidity 55 ± 5 % and twenty air changes per
h. The rats had free access to food and tap water. The exper-
iment was conducted according to the Guidelines for Care and
Use of Experimental Animals, and the protocol was approved
by the Norwegian State Board of Biological Experiments with
Living Animals.
Induction of colitis
DSS (MW 44000; TdB Consultancy AB) at 50 g/l was admi-
nistered in drinking water as previously described(16) for 7 d to
induce colitis.
Experimental protocol
The rats were acclimatised for 7 d and then separated into five
groups of ten rats. The following diets were given: (1) control,
(2) DSS + control, (3) DSS + FO (5 %), (4) DSS + FP (3·5 %)
and (5) DSS + FO+FP. All groups had free access to food
on days 1–29, and DSS was administered during the last week
of the experiment in groups 2–5. All rats were killed the day
after DSS treatment was discontinued – on day 30. At that
time the animals were anaesthetised by inhalation of Isoflurane
(2 %; ‘Isoba vet’, Intervet/Schering-Plough Animal Health) in
an anaesthesia chamber. Thoracotomy, cardiac puncture and
exsanguination were then performed.
Diet composition
The control diet consisted of a standard casein diet with 20 %
(w/w) protein (Sigma-Aldrich), and 7 % fat, composed of 5 %
lard (a generous gift from Ten Kate Vetten BV) and 2 % soya-
bean oil (Dyets Inc.). Lard was replaced by 5 % FO in group 3
(EPAX 4020 TG, EPAX AS), and casein partly by 3·5 % FP
hydrolysate (Marine BioProducts AS) in group 4, and both in
group 5. The FP were produced from salmon by-products
(spine) by enzymatic hydrolysis using controlled autolysis with
commercial proteases. The resulting hydrolysate was further
fractionated using different forms of filtration including ultra-
filtration. The sizes of the peptides were <10 000 Da, with
70 % of total peptides <1000 Da. The final product consisted
of >90 % peptides. The other constituents of the diets were
maize starch, dyetrose, sucrose, fibre, American Institute of
Nutrition (AIN)-93G mineral mix, AIN-93 vitamin mix,
Table 1. Composition of the experimental diets (g/kg diet)*
Ingredients Control FO FP FO+ FP
FO 50 50
Lard 50 50
Soyabean oil 20 20 20 20
FP 35 35
Casein 200 200 165 165
Maize starch 397 397 397 397
Dyetrose 132 132 132 132
Sucrose 100 100 100 100
Fibre 50 50 50 50
AIN-93G mineral mix 35 35 35 35
AIN-93 vitamin mix 10 10 10 10
L-Cysteine 3 3 3 3
Choline bitartrate 2·5 2·5 2·5 2·5
tert-Butyl-hydroquinone 0·014 0·014 0·014 0·014
FO, fish oil; FP, fish peptides; AIN, American Institute of Nutrition.
* The diets were isonitrogenous and isoenergetic.
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L-cysteine, choline bitartrate (Dyets Inc.), and tert-butyl-
hydroquinone (Sigma-Aldrich) (Table 1).
Weight, food intake and disease activity
Body weight and food intake were measured before DSS
administration (day 23) and daily during DSS intake days
24–29. The disease activity index (DAI) is a composite score
where weight loss, stool consistency and rectal bleeding are
rated from 0 to 4, and the total sum is divided by 3(17).
DAI was assessed on the last day of colitis induction (day 30).
Fatty acid composition of the diets
The fatty acids were measured as previously described(17).
Sample collection
After killing, the major part of the colon, from the colocaecal
junction to the anal verge was removed, and the length was
measured unstretched. The colon was rinsed in PBS, and
samples from both the ends and the middle part were separ-
ated, then divided longitudinally and placed in 10 % parafor-
maldehyde. The samples were later embedded in paraffin
and sectioned before staining with haematoxylin and eosin
for histopathological examination. The remaining colon was
divided into one distal and proximal segment. Pieces from
both segments were cooled in liquid N2, freeze clamped and
then stored at −80°C for further analyses.
Further analyses
Colon specimen. In the haematoxylin and eosin-stained
tissue samples, the crypt and inflammatory scores were
determined according to a validated scoring system(18) and
examined by a pathologist unaware of the experimental
protocol. Crypt injury and inflammation severity scores were
assessed as described earlier(17). Both the crypt and
inflammatory score include a measure of involvement: grade
1, 1–25 %; grade 2, 26–50 %; grade 3, 51–75 %; grade 4,
76–100 %. The score is the product of either the crypt
grade by involvement grade or inflammation grade by the
involvement grade. The histological combined score (HCS)
was the sum of the crypt and inflammation scores, and was
measured in all three locations of the colon.
Preparations for tissue cytokine measurements. Full wall
sections of the colon were used, and 50 mg samples were
homogenised and prepared as described previously(17).
Tissue cytokine analyses. Custom-made rat cytokine four-
plex kits including IL-1β, IL-5, interferon-γ and keratinocyte
chemoattractant (KC)/growth-regulated oncogene (GRO) and
single-plex kits with TNFα (Meso Scale Discovery) were
used to measure cytokines in the supernatant from the
homogenisate. The analyses were performed according to the
manufacturer’s recommendations. Results are given as μg/kg
(wet tissue).
PG. Chemicals, solutions and sample preparation of frozen
colon tissue samples (12–35 mg)were performed as described(17).
LC/MS/MS. The LC system was an Agilent 1200 Series with a
binary pump, a variable volume injector and a thermostated
autosampler. HPLC separation was conducted as described(17).
Multiple reaction monitoring for data acquisition and negative
ion detection was used. MassHunter software (Agilent) was
used for HPLC system control, data acquisition and data
processing. The PG analysed are expressed as μg/kg (wet tissue).
Markers of oxidative stress. Glutamic semialdehyde is a
carbonyl product that results from direct oxidative damage
of amino acids (arginyl and prolyl residues). Carboxyethyl-
lysine is derived from glycosylation reactions on proteins
and carboxymethyl-lysine from both glycoxidation and
lipoxidation reactions. Glutamic semialdehyde, carboxymethyl-
lysine and carboxyethyl-lysine concentrations were determined
as trifluoroacetic acid methyl esters derivates in acid-
hydrolysed, delipidated and reduced intestine protein samples.
Homogenisates were measured by GC/MS as previously
described(19). Protein samples were prepared, and internal
standards were added as described(17,19). GC/MS analyses
were carried out as previously described(17). Quantification
was performed by external standardisation using standard
curves constructed from mixtures of 2H-labelled and
non-2H-labelled standards. Analytes were detected by selected
ion-monitoring GC/MS(17). The amounts of products were
expressed as the ratio of micromol per mol lysine.
Gene expression analysis. Total cellular RNA was purified
from 20 mg frozen tissue samples from distal colon, RNA
was quantified spectrophotometrically, and the quality was
evaluated as described(17). For each sample, 4 µg total RNA
was reversely transcribed in 100 µl reactions as previously
reported(17). Real-time PCR was performed with
custom-made 384-well microfluidic plates (Taq-Man Low
Density Arrays; Applied Biosystems) on the following genes:
Il-1b, Rn00580432_m1; Il-6, Rn 00561420; KC-GRO (KC/
GRO, Cxcl1), Rn00578225_m1; inducible nitric oxide
synthase 2 (Nos2), Rn00561646_m1; PPARγ (Pparg),
Rn00440945; PPARγ cofactor 1α (Ppargc-1a), Rn00580241;
Sirtuin 1 (Sirt1), Rn01428093_m1; PGD2 synthase (Ptgds),
Rn00564605_m1; PGE synthase (Ptges), Rn00572047_m1;
PG-endoperoxide synthase 2 (Cox-2, Ptgs2), Rn01483828_m1.
All probes and primers were obtained from Applied
Biosystems. Two different control genes were included:
18s (Kit-FAM-TAMRA (reference RT-CKFT-18s)) from
Eurogentec; and Rplp0 (Rn00821065_g1) from Applied
Biosystems. To normalise the absolute quantification accord-
ing to the reference genes, a second set of PCR was performed
for all experimental samples, and the relative abundance values
were calculated for the reference genes as well as for the target
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genes using standard curves derived from Universal Rat
Reference RNA (Agilent Technologies Inc.). NormFinder(20)
software was used to evaluate the reference genes, and the rela-
tive abundance value of each gene in each sample was normal-
ised against the value of the most stable reference gene, Rplp0.
Statistics
The Shapiro-Wilk test was used to test for normality of data.
The Student’s t test or one-way ANOVA was used to analyse
differences between two or more groups, respectively. The
Mann–Whitney rank test or the Kruskal–Wallis test was applied
in not normally distributed data for two or more groups. Post hoc
tests were performed by the Mann–Whitney rank test. A total of
four pre-determined pairwise differences were analysed: FP v.
DSS, FO v. DSS, FP v. FO and FO v. FO + FP. Bonferroni
corrections were made in the case of multiple group analyses.
For all tests a P value ≤0·05 was considered as statistically
significant. SPSS 15.0 and PASW Statistics 18 statistical software
packages were used for analyses (SPSS Inc.). Bonferroni correc-
tions were not performed in the gene expression analyses.
Results
Fatty acid composition in the diets
As intended, the FO and FO+ FP diets contained large rela-
tive amounts of EPA and DHA, as well as a high total level of
n-3 PUFA. The FP diet had low levels of n-3 PUFA, similar to
the control diet. In the FO-containing diets, we observed a
relative decrease in levels of 18 : 1n-9 as the n-3 PUFA levels
increased (Table 2).
Weight gain, feed intake and dextran sulfate sodium intake
During DSS intake all animal groups lost weight significantly
compared with the control group, which in contrast gained
weight. Feed intake was similar in the DSS-exposed groups,
while the controls had higher food consumption (Table 3).
Of the animals in the FO+ FP group, two died during the
DSS week.
Histological combined score
When dividing all DSS-exposed rats into groups according to
the proximal, middle or distal colon segment, there was a
significant difference in HCS between the three segments
(P = 0·001). Post hoc analyses showed a significantly higher
HCS in the distal and middle colon segments v. the proximal
segment (P = 0·002 for both differences). In the distal colon,
the DSS group had a significantly higher HCS than con-
trols(17). There was an almost significant difference between
DSS-exposed groups (P = 0·07). Post hoc analyses showed a
reduced HCS after the FP diet (median 13·5; range 8–21) v.
the FO diet (median 19; range 15–28) (P = 0·03). Neither
FO nor FP reduced HCS v. DSS (median 17·5; range 1–20)
(P = 1·0 for both differences). HCS did not differ significantly
between FO and FO+ FP (median 15; range 4–21) (P = 0·08)
(Table 4). Histology sections illustrating the median HCS from
all study groups are shown in Fig. 1.
Disease activity index
The median DAI value in the DSS group was higher than in
the control group(17). DAI differed significantly between
DSS-exposed groups (P = 0·02). Post hoc tests showed no
significant reduction of DAI in the FP group (median 1·3;
range 0·7–3·7) v. the FO group (median 2·8; range 1·3 – 3·7)
(P = 0·07). DAI was higher after the FO diet than after DSS
alone (median 1·0; range 0·3 – 3·0) (P= 0·04). DAI did not
differ between FP and DSS (P= 1·0), and did not differ
in the FO v. the FO+ FP group (median 1·3 range 0·7 –
3·7) (P = 0·6) (Table 4).
Table 2. Fatty acid compositions of the diets*
Control FO FP FO+ FP
14 : 0 1·29 0·69 1·31 0·65
16 : 0 20·76 5·55 21·83 5·52
16 : 1n-7 1·21 1·05 1·28 1·08
18 : 0 12·30 3·31 13·10 3·31
18 : 1n-9 29·53 10·49 31·21 10·58
18 : 1n-7 1·93 2·18 2·05 2·23
18 : 2n-6 22·10 14·99 23·23 15·22
18 : 3n-3 2·57 2·24 2·70 2·27
18 : 4n-3 0·003 1·28 0·006 1·32
20 : 4n-6 0·14 1·31 0·15 1·33
20 : 5n-3 0·02 25·63 0·07 26·08
22 : 5n-3 0·01 3·50 0·03 3·50
22 : 6n-3 0·03 19·24 0·07 19·35
SFA 35·64 10·85 37·53 10·71
MUFA 33·60 16·21 35·52 16·37
PUFA (n-3) 2·74 54·31 2·98 54·98
PUFA (n-6) 22·69 18·48 23·86 17·81
PUFA (n-3:n-6) 0·12 2·94 0·12 3·09
DBI 0·88 3·44 0·93 3·44
FO, fish oil; FP, fish peptides; DBI, double bond index.




The controls had a significantly longer colon than the DSS
group, reflecting a colitis-induced shortening after DSS
exposure(17). There were no differences in colon length between
the DSS-exposed groups (P= 0·20), but there was a tendency
to have a longer colon in the FP group (data not shown).
PG
PGE3 levels were significantly different between the DSS-
exposed groups in the distal colon (P= 0·001). Post hoc analyses
showed that the FO diet increased PGE3 levels v. DSS alone.
PGE3 levels were not significantly different in the FP v. the
DSS group. The combined FO+ FP group gave an additional
increase of PGE3 as compared with the FO group (Table 5).
In the case of PGE2, the difference between DSS groups was
significant (P= 0·04) in the distal colon. However, none of the
preselected post hoc tests revealed any differences. The largest
difference in PGE2 levels occurred between the DSS and
the FO+ FP group. For PGD2, a significant difference (P=
0·04), was detected between DSS groups. In the distal colon,
the FO + FP diet increased PGD2 compared with FO
(Table 5).
Gene expression
The expression of mRNA was significantly increased after DSS
alone v. control for several selected genes, including Il-6, Il-1b,
Cxcl1 and Ptges(17). The FP diet reduced the mRNA levels of
these genes compared with DSS alone, although not reaching
significant levels. Nos2 expression was significantly different
between the DSS-exposed groups (P < 0·05). FP, FO and
FO+ FP diets increased Nos2 mRNA levels v. DSS, although
only significantly for the FO + FP diet (Table 5).
Cytokines
The protein levels of TNFα, IL-1β and KC/GRO in the distal
colon were in accord with mRNA levels. All three cytokines
were significantly higher in the DSS animals v. the controls(17).
KC/GRO was close to significantly different between the
DSS-exposed groups (P = 0·07). Post hoc tests revealed that
the FP diet significantly lowered the KC/GRO levels v. the
FO diet. The other preselected pairs analysed showed no sig-
nificant differences. No significant differences in TNFα or
IL-β occurred between groups that received DSS.
Markers of oxidative stress
No significant differences were detected between the DSS-
exposed groups or between selected pairs for the three markers
(data not shown). The levels were higher in the DSS v. the con-
trols for all three markers although not reaching significance.
We noted that, compared with DSS, median levels of all
three markers tended to decrease after FO, while carboxyethyl-
lysine and carboxymethyl-lysine levels were lower after FP,
although not significantly.
Table 3. Average weight gain (%) and feed intake per Wistar rat (g/d) during the dextran sodium sulfate (DSS) week†
(Mean values with their standard errors for nine or ten animals per group)
Weight gain in DSS week
(% per week)
Feed intake in DSS week
(g/d per rat)
Treatment Mean SEM Mean SEM
DSS intake in DSS
week (ml/g rat)
Control 4·62 1·48 21·55 0·75 −
Control + DSS −6·50* 3·16 15·70 0·82 0·30
FO +DSS −9·88* 2·69 14·54 1·18 0·36
FP + DSS −6·84* 5·34 16·17 0·63 0·27
FO + FP +DSS −8·90* 5·00 16·18 0·86 0·47
FO, fish oil; FP, fish peptides.
* Mean value was significantly different from that of the control group (P ≤ 0·05; one-way ANOVA, performed only on the weight results).
† Diets were FO, FP or a combination (FO + FP) for 4 weeks, with DSS exposure in the last week of the experiment.
Table 4. Histological combined scores (HCS) and disease activity index (DAI) in distal colon sections of Wistar rats fed fish oil (FO), fish peptides (FP) or a
combination (FO + FP) for 4 weeks, and treated with dextran sodium sulfate (DSS) during the last week of the experiment
(Median values and ranges)
HCS DAI HCS post hoc* DAI post hoc*
Treatment Median Range Median Range Pair P Pair P
Control 4·0 0–12 0 0–0
Control + DSS 17·5 1–20 1·0 0·3–3·0 FO v. DSS 1·0 FO v. DSS 0·04
FO +DSS 19·0 15–28 2·8 1·3–3·7 FO v. FP 0·03 FO v. FP 0·07
FP + DSS 13·5 8–21 1·3 0·7–3·7 FP v. DSS 1·0 FP v. DSS 1·0
FO + FP +DSS 15·0 4–21 1·3 0·7–3·7 FO v. FO + FP 0·08 FO v. FO + FP 0·6
* Post hoc tests analysed by the Mann–Whitney rank test.
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Fig. 1. Micrograph panels. (a) Normal colonic mucosa from a healthy control rat. (b) Colonic mucosa from a rat with dextran sulfate sodium (DSS) colitis showing
crypt destruction and moderate inflammation, with almost intact epithelium. (c) Colonic mucosa from a rat after DSS and fish oil (FO) diet showing crypt destruction,
severe inflammation and ulcerated surface. (d) Colonic mucosa from a rat after DSS and fish peptides (FP) diet showing some preserved normal crypts and some
crypt destruction, moderate inflammation and intact epithelium. (e) Colonic mucosa from a rat after FO + FP diet showing destruction of most crypts, moderate inflam-
mation and lost epithelium. Haematoxylin and eosin staining, magnification, ×400.
Table 5. Selected gene expression, and cytokine and prostaglandin levels in distal colon sections of Wistar rats fed fish oil (FO), fish peptides (FP) or a
combination (FO + FP) for 4 weeks, and treated with dextran sodium sulfate (DSS) during the last week of the experiment†
(Median values and ranges)
Control DSS DSS + FO DSS + FP DSS + FO+ FP
Median Range Median Range Median Range Median Range Median Range
Gene
Nos2 1·00 0·33–20·4 58·5**a 0·95–251 272b 99·8–442
Cytokine
KC/GRO 0·70 0·38–1·12 5·03** 0·47–180 12·0a 5·07–124 3·20b 1·13–64·6
Prostaglandins
PGE3 0 0–0 0
a 0–0·73 13·8b 2·50–34·6 1·53a,c 0–17·2 35·9c 10·2–111
PGD2 96·2 27·5–507 102a 20·8–272 79·3a 41·4–156 210b 51·9–343
Nos2, inducible nitric oxide synthase 2; KC, keratinocyte chemoattractant; GRO, growth-regulated oncogene.
a,b,c Median values for the DSS groups with unlike superscript letters were significantly different (P < 0·05 (Kruskal–Wallis test/Mann–Whitney post hoc test) except KC/GRO:
P = 0·07 (Kruskall–Wallis test)).
** Median value was significantly different from that of the control treatment (P < 0·01; Mann–Whitney rank test).
† Nos2 expression values were normalised against an endogenous control, and variables are given as medians relative to control (n 7–8). Cytokine and prostaglandin levels (μg/kg




The main findings of this study are that hydrolysed salmon
peptides, a novel dietary component used in IBD models, atte-
nuated DSS-induced colitis as compared with FO. This was
observed by fewer signs of histopathological inflammation,
less clinical disease activity, a lowered inflammatory cytokine
signature at the protein and mRNA levels, and increased
PGD2. Also, the FP diet improved a number of variables
when compared with animals fed DSS alone, such as cytokines
and markers of protein oxidation, although not reaching stat-
istical difference. In addition, we observed that the expected
increase of PGE3 induced through metabolism of EPA
from dietary FO increased further after combining FO and
FP in the diet.
Although intake of FPhas not beenmuch investigated in exper-
imental colitis, other dietary bioactive peptides have shown anti-
inflammatory effects in IBD animal models(21). An intestinal
protective effect from fish hydrolysate was suggested, as prolifer-
ation ofHT29 cells increased, while indomethacin-induced apop-
tose and small-intestinal villous damagewere decreased inmice(9).
Moreover, intake offish protein hydrolysate containing 75 – 80 %
protein constituents in healthy humans reduced small-intestinal
damage caused by indomethacin(10). The proposed mechanisms
in these two studies were the presence of glutamine (14 – 16 %
of the total), an antioxidant effect, and an effect of the 6 – 10 %
content of FO in the hydrolysate. The doses of 25 – 50 g/l and
3 g daily used in their studies are not directly comparable with
35 g/kg used in our study. FP contained > 90 % peptides, but
had a lower glutamine content of 8·5 % (w/w). Glutamine, a
substrate for enterocyte metabolism, could act protectively by
preserving intestinal integrity and barrier function, as shown in
previous experimental colitis models(22). The n-3 content in FP
was only 3·0 %, similar to the controls in our study (2·7 %),
and can probably not explain the beneficial changes after the
FP diet. Specific structural features have been linked to potentially
bioactive peptides; the molecular weight should be <10 kDa,
most preferably <1 kDa, and the size of peptides between two
and twenty amino acids(23). Our FP product is within this range.
DSS-induced experimental colitis has some similarities to
the human disease UC. Epithelial injury is fundamental in
this model, and during the acute colitis phase innate immune
responses are activated(24). The pro-inflammatory cytokine
levels in the DSS model were at their lowest after the FP
diet at both the protein and mRNA levels, suggesting an anti-
inflammatory effect from bioactive FP, influencing innate
immunity. PGD2 reduces granulocyte infiltration in exper-
imental colitis(25), and its synthesis is up-regulated in UC
patients in remission(26). The tendency for PGD2 to increase
after FP diets in our study may point to a protective effect.
Contrary to expectations, FO did not improve signs of coli-
tis. As compared to DSS, HCS was unaltered and DAI
increased. Other variables were not significantly altered. This
is in contrast to previous trials with dietary n-3 PUFA admin-
istration in experimental colitis, which has generally shown
beneficial effects(27–29). The fatty acid analysis of the diets con-
firmed large relative amounts of EPA and DHA in the two
FO diets, with an n-3:n-6 ratio in the feed of 2·9 and 3·1.
The relatively anti-inflammatory eicosanoid PGE3 was
increased, which is expected after dietary intake of EPA. In
our study however, vitamin E or other anti-oxidants were
not added to the diets containing FO. This could result in
increased lipid peroxidation and oxidative stress in the colonic
mucosa, which could counteract an anti-inflammatory
effect(30). However, the levels of oxidation markers in our
study were not increased, but rather tended to decrease,
after the FO diet.
When combining FO and FP diets we observed that the
PGE3 levels increased as compared to the FO diet. The reason
for this is unclear, as adding the FP diet did not provide high
amounts of EPA. FP, when combined with the FO diet, could
possibly influence the enzymatic activity of cox2, thus leading
to elevated PGE3 synthesis. We observed that the mRNA
levels of ptgs2/cox2 as well as ptges were elevated in the com-
bined FO+ FP group v. FO, but not reaching significance.
Nos2 expression was elevated after DSS v. controls, and was
significantly increased after the FO+ FP diet v. DSS alone.
NO is a result of inducible NO synthase expression, and
seems to have a dual role. It may provide either anti-
inflammatory or toxic effects(31). Thus, the higher Nos2 levels
after the FO + FP diet may be a protective response, sup-
ported by the PGE3 and PGD2 increase, or it may be detri-
mental, as suggested by a tendency for elevated HCS and
cytokine levels.
This study has its limitations: antioxidant added to the FO
diets might have influenced the results. An increased number
of rats in each group would have increased the statistical power
of the analyses. Statistical analysis regarding feed and DSS
intake could not be performed. We induced a severe colitis,
leading to death in two animals, by administering 5 % DSS
for 1 week, which could limit the detection of modest ben-
eficial effects. The diets used might affect the healing time
of the colitis after stopping DSS. The effects observed may
be due to prophylactic as well as therapeutic potential of the
diets, as the study design cannot differentiate between these
aspects. The DSS model clearly has limitations as a substitute
for the human disease, as a chemically induced injury model
instead of an endogenously triggered inflammation.
In conclusion, dietary hydrolysed salmon peptides may offer
protection against DSS colitis as compared with a FO diet, but
do not improve inflammatory variables significantly when
compared with DSS alone. A combined diet may affect eico-
sanoid metabolism by increasing PGE3 levels, although not
attenuating other signs of colon inflammation. Hydrolysed sal-
mon peptides should be further investigated as a dietary inter-
vention against inflammation in animal models, as well as in
patients with IBD.
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